Industrial Policy & Trade Monitor· 2663 actions· ✨ 89 recent

The Beijing Economic-Technological Development Zone (BDA / Yizhuang) Management Committee issued "Several Measures on Accelerating Brain-Computer Interface Technology and Industry Innovation Development" (Jingjiguanfa [2026] No. 2), announced 2026-02-04 and effective 2026-02-06 through 2028-12-31. The package comprises 15 initiatives across three pillars — technology/product development, innovation platform construction, and industrial ecosystem building — aimed at moving the BCI sector from research toward clinical translation and commercialization, positioning Yizhuang as a leading domestic and internationally recognized BCI technology and industry hub. It applies to entities legally operating in Yizhuang New City engaged in BCI R&D, product manufacturing, or platform services. No specific monetary figures are disclosed in the published policy interpretation.

On 26 January 2026 Beijing's Dongcheng District (via the Zhongguancun Science Park Dongcheng Zone Management Committee and the district Science and Technology Commission) issued Notice 东城园文〔2026〕2号, "Several Measures of Beijing Dongcheng District on Promoting High-Quality Development of the Pharmaceutical and Health Industry," effective 25 February 2026. The 14-article package spans seven chapters covering traditional-Chinese-medicine industry development, product-innovation value realisation, digital medical services, innovative-medicine support, and talent services, with cash grants of up to RMB 20 million per project and up to RMB 10 million per year for a single market entity in the medical-device segment. A draft version was open for public comment from 18 December 2025 to 17 January 2026 before formal issuance.

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, took a AUD 20 million preferred-equity stake in Omniscient Neurotechnology, a Sydney-founded clinical connectomics company, announced 16 January 2026. The investment forms part of Omniscient's broader Series D raise (reported at up to AUD 36 million / USD 27.2 million) alongside Australian venture fund OIF Ventures, and is earmarked to commercialise Omniscient's Quicktome AI brain-mapping platform globally and expand its data-science team. NRFC frames the deal as building sovereign AI/medical-technology capability and creating over 40 new skilled jobs in Australia.

On 25 December 2025 Shanghai's Huangpu District Science and Technology Commission and Investment Promotion Office jointly issued Huangkeweigui [2025] No. 3, "Several Measures of Huangpu District on Promoting Brain-Computer Interface Innovation and Transformation Services (Trial)" (informally the "BCI Service 10 Provisions"), effective 24 January 2026 and valid through 31 December 2027. The measures subsidize BCI core- technology R&D and district co-funding of national/municipal projects (up to CNY 2m, 1:1 district match), shared innovation-platform construction (up to 30% of investment, capped CNY 2m), registered medical-device commercialisation (up to 40% of R&D cost, capped CNY 5m/ year per entity), application-demonstration scenarios (up to 30% of investment, capped CNY 2m), enterprise-growth and unicorn/gazelle recognition rewards (CNY 20k-100k), industrial-park operator support (up to CNY 2m/year), equity-financing support (up to 10% of R&D cost, capped CNY 2m, for firms with ≥CNY 20m in equity funding), and international BCI conference/event sponsorship (up to 30%, capped CNY 500k).

On 24 November 2025, six Beijing municipal departments — the Bureau of Economy and Information Technology, Development and Reform Commission, Science and Technology Commission, Health Commission, Drug Administration and Medical Insurance Bureau — jointly issued Notice 京经信发〔2025〕50号 ("Several Measures to Promote High-Quality Development of the Beijing Medical Device Industry"), effective immediately through 31 December 2028. The 15-measure package subsidises the full medical-device value chain: early-stage innovation (up to RMB 1m per project), product approval/launch (up to RMB 2m per product, RMB 10m annual enterprise cap), industrial-park and public-service infrastructure construction (up to 50% of investment, capped at RMB 50m), supply-chain-resilience R&D for critical components/materials (up to 30% of investment, capped at RMB 30m), AI-diagnostic-model development (up to RMB 30m), smart-factory digitalisation (up to 30% of investment, capped at RMB 30m per project), and international regulatory approval/market entry (up to RMB 1m per product, RMB 3m annual cap; up to RMB 10m for introducing overseas products to China).

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, took a AUD 54 million (~USD 35 million) equity stake in Synchron, a Melbourne-founded (now US-headquartered) brain-computer interface company, announced 7 November 2025. The investment forms part of Synchron's broader ~AUD 305-308 million (~USD 200 million) Series D raise alongside investors including Qatar Investment Authority, In-Q-Tel and Double Point Ventures, and is earmarked to fund final clinical trials and US FDA regulatory approval of Synchron's Stentrode device — a minimally-invasive BCI implanted via blood vessel without open brain surgery. NRFC frames the deal as commercialising Australian-origin technology and building sovereign medical-device manufacturing and clinical-trial capability.

The European Investment Bank (EIB) signed a EUR 400 million loan agreement with Fresenius on 8 September 2025 in Bad Homburg, Germany, to finance research, development and innovation activities and capacity expansion for Fresenius Kabi's manufacturing of biosimilars, generic drugs, infusion therapies, clinical nutrition products, and associated medical devices across EU member states. The financing is explicitly framed by both parties as strengthening the resilience of European pharmaceutical production and security of supply for EU healthcare systems.

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, committed AUD 150 million to Brandon Capital's Brandon BioCatalyst 6 (BB6) fund, announced 24 July 2025. Brandon Capital — Australasia's largest life-sciences venture capital manager, with over AUD 1 billion under management — closed BB6 at AUD 439 million total, with the NRFC contribution the largest single commitment. The fund backs early- and late-stage Australian medical-science companies developing therapeutics, medical devices and vaccines, with roughly one-third earmarked for early-stage ventures and the remainder for late-stage clinical development and commercialisation. NRFC frames the deal as building sovereign medical-manufacturing and R&D capability and keeping Australian biotech IP and jobs onshore rather than migrating offshore for follow-on capital.

The European Commission approved up to EUR 403 million in State aid from France, Hungary, Italy, Slovakia and Slovenia to fund Tech4Cure, the second health-related Important Project of Common European Interest (IPCEI). The scheme backs ten companies (including six SMEs) on R&D and first industrial deployment of medical devices integrating digital and AI technologies across cardiovascular disease, paediatrics, oncology, neonatal care and ophthalmology, targeting "3P" (predictive, preventive, personalised) medicine. The Commission expects the public funding to leverage an additional EUR 826 million in private investment.

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, took a AUD 27 million equity stake in PolyActiva, a Melbourne biotech developing a biodegradable ocular implant (Prezia/PA5108) that delivers glaucoma medication over 6-12 months as an alternative to daily eye drops. The investment, announced 30 May 2025, forms the majority of PolyActiva's AUD 40 million Series C round, with the remaining AUD 13 million from existing investor Brandon Capital. Funds will consolidate the company's R&D, analytics and manufacturing into a single Melbourne facility, grow its ~25-person workforce, and fund completion of a Phase 2b clinical trial, with commercialisation targeted for 2029.